Michael Panzara

14.2k citations

80 papers · 10.2k indexed · 5 hit papers · h-index 28

Impact in

Pathology and Forensic Medicine top 0.02%
- Multiple Sclerosis Research Studies
Neurology top 0.2%
- Peripheral Neuropathies and Disorders

Papers in

Pathology and Forensic Medicine 47
- Multiple Sclerosis Research Studies 45
Rheumatology 19
- Rheumatoid Arthritis Research and Therapies 14

Co-authors: Eva Havrdová Frances Lynn Douglas L. Arnold Fred Lublin Alfred Sandrock Christian Confavreux Michael Hutchinson David H. Miller
Journals: Neurology (37 papers)Multiple Sclerosis Journal (4 papers)Journal of Neurology (4 papers)Journal of the Neurological Sciences (4 papers)Journal of Neuroimmunology (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Michael Panzara

79 papers receiving 9.9k citations

Hit Papers

5 papers align trajectories log scale

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial 2012 · 883 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 The Lancet
2012 The Lancet
2008 New England Journal of Medicine
2006 New England Journal of Medicine
2006 New England Journal of Medicine

Peers

Countries citing papers authored by Michael Panzara

Since Specialization

Citations

This map shows the geographic impact of Michael Panzara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Panzara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Panzara more than expected).

Fields of papers citing papers by Michael Panzara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Panzara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Panzara. The network helps show where Michael Panzara may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Panzara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Panzara Line = papers co-authored together Michael Panzara links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community Multiple Sclerosis Journal ·Alan J. Thompson, Marcello Moccia, Maria Pia Amato, Peter A. Calabresi, Marcia Finlayson, Annie Hawton, Fred Lublin, Ruth Ann Marrie, Xavier Montalbán, Michael Panzara, Maria Pia Sormani, Audeh G. Rantisi, Barbara G. Vickrey, Timothy Coetzee	2023	4
2	Frequency of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease (HD): Results from a Prospective Observational Research Study (P4.037) Neurology ·Daniel O. Claassen, Mary Edmondson, Ralf Reilmann, Nenad Svrzikapa, Kenneth Longo, Jaya Goyal, Serena Hung, Michael Panzara	2018	1
3	Alemtuzumab CARE-MS I 5-year follow-up Neurology ·Eva Havrdová, Douglas L. Arnold, Jeffrey Cohen, Hans‐Peter Hartung, Edward Fox, Gavin Giovannoni, Sven Schippling, Krzysztof Selmaj, Anthony Traboulsee, D. A. S. Compston, David Margolin, Karthinathan Thangavelu, Hamburg Spies, D. Jody, Richard Hogan, Kiyoto Maki, Michael Panzara, Alasdair Coles	2017	176
4	Slowing of Brain Volume Loss in Patients With Relapsing-Remitting Multiple Sclerosis After Switching From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.264) Neurology ·Jeffrey Cohen, Douglas L. Arnold, Alasdair Coles, Edward Fox, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D. A. S. Compston	2015	2
5	Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7.278) Neurology ·Edward Fox, Gavin Giovannoni, Douglas L. Arnold, Alasdair Coles, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, David Margolin, Jeffrey Palmer, Michael Panzara, D. A. S. Compston	2015	2
6	Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263) Neurology ·Alasdair Coles, Douglas L. Arnold, Jeffrey A. Cohen, Edward Fox, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D. A. S. Compston	2015	4
7	Durable Effect of Alemtuzumab on Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.276) Neurology ·Eva Havrdová, Gavin Giovannoni, Douglas L. Arnold, Alasdair Coles, Edward Fox, Hans‐Peter Hartung, Krzysztof Selmaj, David Margolin, Jeffrey Palmer, Michael Panzara, D. A. S. Compston	2015	3
8	Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093) Neurology ·Hans Hartung, Timothy Vollmer, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Cary Twyman, Tamara Miller, Stephen Lake, David Margolin, Michael Panzara, Alastair Compston	2013	2
9	Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) Neurology ·Per Soelberg Sørensen, Douglas L. Arnold, Jeffrey A. Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Cary Twyman, Stephen Lake, David Margolin, Susan Richards, Crystal Sung, Michael Panzara, Alastair Compston	2013	4
10	Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) Neurology ·Gavin Giovannoni, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Cary Twyman, Tamara Miller, Stephen Lake, David Margolin, Michael Panzara, Alastair Compston	2013	1
11	Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172) Neurology ·Sibyl Wray, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Cary Twyman, Stephen Lake, David Margolin, Michael Panzara, Alastair Compston	2013	1
12	Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174) Neurology ·Christopher LaGanke, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Cary Twyman, Stephen Lake, David Margolin, Michael Panzara, Alastair Compston	2013	3
13	Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) Neurology ·Edward Fox, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Cary Twyman, Anton Vladić, David Margolin, Pedro Oyuela, Michael Panzara, Alastair Compston	2013	11
14	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial The Lancet ·Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Elizabeth Fisher, Vesna Brinar, Gavin Giovannoni, M. Stojanovic, Bella Ertik, Stephen Lake, David Margolin, Michael Panzara, D. A. S. Compston Hit paper breakdown →	2012	883
15	PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis Journal of Interferon & Cytokine Research ·Darren P. Baker, R. Blake Pepinsky, Margot Brickelmaier, Robert S. Gronke, Xiao Hu, Kenneth N. Olivier, Michaela Lerner, Larisa Miller, Mary Crossman, Ivan Nestorov, Meena Subramanyam, Dun-Ru Zhu, Suk‐Zu Song, Sandra Richman, Shifang Liu, Ying Zhu, Michael Panzara, Gudarz Davar	2010	32
16	The incidence and significance of anti-natalizumab antibodies Neurology ·Peter A. Calabresi, Gavin Giovannoni, Christian Confavreux, Steven Galetta, Eva Havrdová, Michael Hutchinson, Ludwig Kappos, D. H. Miller, Paul O’Connor, J. Theodore Phillips, Chris H. Polman, Ernst W. Radue, R. A. Rudick, W. H. Stuart, Fred Lublin, A Wajgt, B. Weinstock‐Guttman, Daniel Wynn, Frances Lynn, Michael Panzara	2007	236
17	Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis Journal of Neurology ·Catherine M. Dalton, Katherine Miszkiel, Gareth J. Barker, David MacManus, Roland Boutte, Michael Panzara, Minhua Yang, P. Steven, Paul O’Connor, David H. Miller, (unknown)	2004	95
18	T Cell Receptor BV Gene Rearrangements in the Spinal Cords and Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis Neurobiology of Disease ·Michael Panzara, Emanuela Gussoni, Ann B. Begovich, Ronald S. Murray, Ying Zang, Stanley H. Appel, Lawrence Steinman, Jingwu Zhang	1999	24
19	Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis Nature ·Jorge R. Oksenberg, Michael Panzara, Ann B. Begovich, Dennis J. Mitchell, (unknown), Ronald S. Murray, Richard Shimonkevitz, Martina A. Sherritt, Jonathan Rothbard, Claude C.A. Bernard, Lawrence Steinman	1993	350
20	Multiple sclerosis: From immunogenetics to immunotherapy Journal of the Neurological Sciences ·Jorge R. Oksenberg, Michael Panzara, Lawrence Steinman	1993	1

About Michael Panzara

Michael Panzara is a scholar working on Pathology and Forensic Medicine, Rheumatology, Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 80 papers that have together received 10.2k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (45 papers), Polyomavirus and related diseases (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers), Immunotherapy and Immune Responses (14 papers), Rheumatoid Arthritis Research and Therapies (14 papers), Muscle Physiology and Disorders (6 papers), Acute Lymphoblastic Leukemia research (6 papers) and T-cell and B-cell Immunology (6 papers). The work is most often cited by research in Pathology and Forensic Medicine (7.5k citations), Neurology (2.7k citations), Immunology (3.4k citations), Rheumatology (1.8k citations) and Oncology (3.3k citations). Michael Panzara has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Eva Havrdová, Frances Lynn, Douglas L. Arnold, Fred Lublin, Alfred Sandrock, Christian Confavreux, Michael Hutchinson, David H. Miller, J. Theodore Phillips and A Wajgt. Their work appears in journals such as Neurology, Multiple Sclerosis Journal, Journal of Neurology, Journal of the Neurological Sciences and Journal of Neuroimmunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact